← Encyclopedia

Definium Therapeutics' lead LSD candidate — lysergide delivered as an orally-disintegrating tablet rather than the traditional blotter or liquid form. Originally developed under the code name MM120 before the company's January 2026 rebrand from MindMed to Definium.

Example: DT120 has posted two independent positive Phase 3 trials for generalized anxiety disorder — Voyage and Panorama — making it the most advanced LSD program in clinical development, though it's still not FDA-approved for anything.